Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Italy Fines Apple €98.6 Million Over App Store Dominance 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
LEXINGTON, Mass., Aug. 31, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a trial-in-progress poster describing preliminary clinical data from the dose escalation stage of CA-170 Phase 1 clinical trial at the European Society for Medical Oncology (ESMO) 2017 Congress. The conference will take place September 8-12 in Madrid. CA-170, an oral small molecule targeting the immune checkpoints PDL1 and VISTA, is in development for the treatment of patients with advanced solid tumors or lymphomas.
Additional information on the presentation can be found below and can be accessed at www.esmo.org.
CA-170 Poster Presentation:
| Date/Time: | Monday, Sept. 11, 9:15 AM – 10:45 AM CEST |
| Abstract Number: | 1141PD |
| CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in | |
| Presentation Title: | pre-clinical models and promotes T cell activation in Phase 1 study |
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
